Second-Line Chemotherapy Combined With Endostatin for Recurrent/Metastatic HN Epithelial Tumors

NCT03989830 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Neoplasms

Interventions

DRUG: second-line chemotherapy
DRUG: Recombinant human endostatin

Sponsor

Sun Yan

Collaborators

[object Object]
[object Object]